Transactivation of HER2 by phosphorylated HER3 and EGFR correlates with clinicopathological end points in HER2 negative NSCLC

被引：0

作者：

Mohan, Kamlesh ^{[1
]}

Dodson, Andrew ^{[2
]}

Gosney, John ^{[2
]}

Carr, Martin ^{[1
]}

Thomas, Andrew ^{[3
]}

Womack, Chris ^{[3
]}

Jenkins, Martin ^{[3
]}

McGuire, Joe ^{[1
]}

Walshaw, Martin ^{[1
]}

Armour, Alison ^{[3
]}

机构：

[1] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England

[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England

[3] Astra Zeneca, Macclesfield, Cheshire, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S897 / S898

页数：2

共 50 条

[1] Novel agents that downregulate EGFR, HER2, and HER3 in parallel
Ferreira, Renan Barroso
Law, Mary Elizabeth
Jahn, Stephan Christopher
Davis, Bradley John
Heldermon, Coy Don
Reinhard, Mary
Castellano, Ronald Keith
Law, Brian Keith
[J]. ONCOTARGET, 2015, 6 (12) : 10445 - 10459
[2] Occurrence of de Novo Dual HER2/HER3 or HER2/EGFR TMD Mutations: Extending the Spectrum of Targetable Mono-HER2 TMD in NSCLC?
Ou, S.
Schrock, A.
Bocharov, E.
Lee, J.
Madison, R.
Gay, L.
Miller, V.
Alexander, B.
Husain, H.
Riess, J.
Ali, S.
Velcheti, V.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S394 - S394
[3] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity
Hanker, Ariella B.
Brown, Benjamin P.
Meiler, Jens
Marin, Arnaldo
Jayanthan, Harikrishna S.
Ye, Dan
Lin, Chang-Ching
Akamatsu, Hiroaki
Lee, Kyung-Min
Chatterjee, Sumanta
Sudhan, Dhivya R.
Servetto, Alberto
Brewer, Monica Red
Koch, James P.
Sheehan, Jonathan H.
He, Jie
Lalani, Alshad S.
Arteaga, Carlos L.
[J]. CANCER CELL, 2021, 39 (08) : 1099 - +
[4] HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR?
Freeman, MR
[J]. CANCER CELL, 2004, 6 (05) : 427 - 428
[5] The involvement of EGFR, HER2 and HER3 in the basal cell carcinomas aggressiveness
Florescu, Diana Elena
Stepan, Alex Emilian
Margaritescu, Claudiu
Ciurea, Raluca Niculina
Stepan, Mioara-Desdemona
Simionescu, Cristiana Eugenia
[J]. ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2018, 59 (02): : 479 - 484
[6] Effects of HER2 and HER3 on EGFR trafficking and localization - a modelling study
Resat, H
Shankaran, H
Wiley, H
[J]. MOLECULAR BIOLOGY OF THE CELL, 2004, 15 : 13A - 13A
[7] The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors
Cirstea, Andreea-Elena
Stepan, Alex Emilian
Margaritescu, Claudiu
Zavoi, Roxana Eugenia
Olimid, Daniel Alin
Simionescu, Cristiana Eugenia
[J]. ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (04): : 1269 - 1273
[8] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
Hanker, Ariella B.
Jayanthan, Harikrishna Sekar
Ye, Dan
Lin, Chang-Ching
Akamatsu, Hiroaki
Sheehan, Jonathan H.
Koch, James P.
Sudhan, Dhivya R.
Brewer, Monica Red
Servetto, Alberto
He, Jie
Miller, Vincent A.
Lalani, Alshad S.
Meiler, Jens
Arteaga, Carlos L.
[J]. CANCER RESEARCH, 2020, 80 (04)
[9] EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases
Qichun Wei
Liming Sheng
Yongjie Shui
Qiongge Hu
Hans Nordgren
Jorgen Carlsson
[J]. Annals of Surgical Oncology, 2008, 15 : 1193 - 1201
[10] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
Melanie Spears
Karen J. Taylor
Alison F. Munro
Carrie A. Cunningham
Elizabeth A. Mallon
Chris J. Twelves
David A. Cameron
Jeremy Thomas
John M. S. Bartlett
[J]. Breast Cancer Research and Treatment, 2012, 132 : 463 - 470

← 1 2 3 4 5 →